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C A S E R E P O R T
Neurosarcoidosis and infliximab therapy monitored
by 18FDG PET/CT
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Learning points for clinicians
• Neurosarcoidosis is a severe disease affecting young
adults with a mortality rate of 5%.
• Cranial nerve palsy, spinal cord disease, seizures or
headaches are the main symptoms.
• 18FDG PET/CT is useful in diagnosing neurosarcoidosis
involving cranial nerves and in monitoring treatment
response under tumor necrosis factor-alpha inhibitors,
such as infliximab.
Background
Neurosarcoidosis is a challenging diagnosis because of the
disease rarity and differential diagnoses that are common to
multiple neurological disorders. The main neurological mani-
festations are cranial nerve palsy (63%), spinal cord disease
(19%), seizures (17%) and headaches (17%).1 Whereas cranial
nerves including facial, optic or trigeminal nerves are common-
ly involved, glossopharyngeal and vagus nerve lesions are rarely
reported (4%).2 According to recently developed criteria,3 in add-
ition to clinical, biological and radiological evidence, histological
analysis is mandatory to maintain a probable or definite
diagnosis of neurosarcoidosis. However, the exact role of 18-flu-
deoxyglucose-positron emission tomography (18FDG PET/CT) is
still unclear in the diagnostic work-up. Here, we report the case
of a 49-year-old man with sarcoidosis relapse presenting with
glossopharyngeal and vagus nerve palsy, diagnosed by 18FDG
PET/CT, and successfully treated with infliximab.
Case report
A 49-year-old man was admitted to our unit in May 2017 for
progressive dysphagia, dysphonia, Horner syndrome of the left
eye and general health deterioration. Sarcoidosis of the lungs
and mediastinal lymph nodes was diagnosed in 2015 following
mediastinal lymph node biopsy and treated with steroids,
but stopped prematurely at 11 months due to psychiatric
side effects. Dysphonia, at the time thought to be related to com-
pression of the left recurrent nerve by the lymph nodes, persisted
despite steroid therapy. Physical examination at admission
revealed an isolated right deviation of the tongue and soft palate
(Figure 1). Routine biological tests demonstrated isolated lympho-
penia (1.109/l). Brain magnetic resonance imaging and cerebro-
spinal fluid analysis were normal. 18FDG PET/CT revealed
significant hypermetabolism of the mediastinal lymph nodes,
liver nodules, the roots of the ninth and 10th cranial nerves and
the upper cervical ganglion (Figure 2A and B). Over 6 months,
other diagnoses were eliminated and sarcoidosis relapse was
confirmed. Prednisone (80 mg/day) and mycophenolate mofetil
(3 g/day) were introduced, however tapering of prednisone at 6
months resulted in relapse. Mycophenolate mofetil was stopped,
and infliximab (5 mg/kg) was added to prednisone (20 mg/day),
which was further tapered (5 mg/day) after 4 months. Symptoms
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progressively disappeared and 18FDG PET/CT at 6 months demon-
strated a complete remission of the disease (Figure 2C and D),
which was also confirmed at 12 months.
Discussion
Neurosarcoidosis is a potentially severe disease affecting young
adults with a mortality rate of 5%.2 The mean age at onset is
43.2 Neurological symptoms are observed in 5% of patients
with systemic sarcoidosis, but are the first signs of sarcoidosis
in 50% of cases.2 Even though facial, ocular, trigeminal and
eighth nerves are frequently involved, overt lesions of the 9th
and 10th cranial nerves and Horner syndrome are rare.2 A lesion
of the second neuron resulting from enlarged upper mediastinal
lymph nodes or a collateral infiltration of the upper cervical
ganglion could explain the Horner syndrome of our patient.
Magnetic resonance imaging can be useful to diagnose brain,
spinal cord, optic or eighth nerve lesions, but may miss lesions
on other cranial nerves.4 As illustrated here, advantages of
18FDG PET/CT in sarcoidosis include:1 providing evidence for the
disease in very tiny regions such as cranial nerves;2 establishing
a pre-therapeutic map of affected organs; and3 guiding the over-
all response to therapy.5
Our case also demonstrates that infliximab can control neu-
rosarcoidosis. In a previously published retrospective study of
66 patients, 29% completely recovered, 48.5% partly recovered,
18% stabilized and 3% worsened.6 Unlike our patient, 74% of
patients had another non-biologic immunosuppressant and
nearly all took steroids.6 Of note, 56% of patients in remission
relapsed at a median of 5.7 months once infliximab was
suspended.6
Taken together, our report highlights the utility of 18FDG
PET/CT in diagnosing neurosarcoidosis involving cranial nerves
and monitoring the treatment response under tumor necrosis
factor-alpha inhibitors, such as infliximab.
Patient consent: The authors obtained patient’s consent to
publish his case.
Figure 1. Right deviation of the tongue and soft palate related to left glossopha-
ryngeal nerve (IX) palsy.
Figure 2. The 3D reconstruction of 18FDG PET/CT images revealing 18FDG uptake of mediastinal lymph nodes, liver nodules, the emergence of left glossopharyngeal
and vagus nerves and the upper cervical ganglion related to sarcoidosis (A, arrow, zoomed in B, standardized uptake value of 8.4), with a complete remission
at 6 months under infliximab therapy (C, zoomed in D).
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